Arthravir-complex-INKAMFARM - instructions for use, doses, side effects, contraindications

Active substances: glucosamine sodium sulfate chloride - 314.0 mg (in terms of glucosamine sulfate - 250.0 mg); chondroitin sodium sulfate - 200.0 mg. Excipients: croscarmellose sodium 20.0 mg, Povidone-K25 5.0 mg, microcrystalline cellulose 36.0 mg, magnesium stearate 5.0 mg.

Capsule composition: Capsule case: titanium dioxide - 2.0%, gelatin - up to 100%.

Capsule cap: Azorubin dye - 0.0821%, Crimson dye [Ponso 4R] - 0,0192%, dye blue patented - 0,1314%, dye diamond black - 0,1533%, titanium dioxide - 2,0%, gelatin - up to 100%.

Description:Capsule number 0.The capsule body is white, the lid is blue, opaque. The contents of the capsules are a mixture of powder and granules with crystalline inclusions, white or white with a yellowish hue of color. Granules of irregular shape, of various sizes, the contents of the capsule can be sealed according to the shape of the capsule.

Pharmacotherapeutic group:Reparation of tissue stimulant

ATX: & nbsp

M.01.A.X Other non-steroidal anti-inflammatory drugs

Pharmacodynamics:

Stimulates the regeneration of cartilaginous tissue. Glucosamine sulfate and chondroitin sulfate participate in the biosynthesis of connective tissue and, as a result, can help prevent cartilage destruction processes and stimulate tissue regeneration.

Pharmacodynamics

Glucosamine sulfate

Glucosamine sulfate is one of the components of the synthesis of hyaluronic acid, which is necessary for the formation of proteoglycans of the structural matrix of joints.

It has also been established that glucosamine sulfate protects articular cartilage from the damaging effects of some non-steroidal anti-inflammatory drugs (NSAIDs). Sulfate ion is necessary for the synthesis of glycosaminoglycans, which are esters of sulfuric acid.The ingestion of exogenous glucosamine stimulates the production of a cartilaginous matrix and provides its nonspecific protection. Glucosamine has a certain anti-inflammatory effect.

Chondroitin sulfate

Chondroitin sulfate, whether absorbed in an intact form or as separate fragments, serves as an additional substrate for the formation of a healthy cartilage matrix. Chondroitin sulfate (and its derivatives) stimulate the formation of hyaluronone, the synthesis of proteoglycans and collagen II type, and also protects the matrix of cartilaginous tissue from enzymatic cleavage (by suppressing the activity of hyaluronidase) and the damaging effect of free radicals. Chondroitin sulfate maintains the viscosity of the synovial fluid, stimulates mechanisms of cartilage repair and inhibits the activity of those enzymes (elastase, hyaluronidase) that break down the cartilage. Chondroitin sulfate in the treatment of osteoarthritis facilitates the symptoms of this disease and reduces the need for NSAIDs.

Pharmacokinetics:

Glucosamine

Absorption

In humans, the bioavailability of glucosamine for oral administration is 25%.

Distribution

After absorption of the oral dose, radiolabeled glucosamine initially found in the components of the plasma and later penetrates into the tissues. The highest concentrations were found in the liver, kidneys and articular cartilage. About 30% of the dose is persistently persistent in the tissues of bones and muscles.

Elimination

The fraction of glucosamine that is not metabolized or does not bind to plasma proteins is excreted mainly by the kidneys. Most of the drug found in the stool after ingestion is an unabsorbed fraction. The final half-life of the drug bound to plasma proteins is 68 h.

Chondroitin sulfate

Absorption

When chondroitin sulfate is taken orally once in a dose of 0.8 g (or twice a day at a dose of 0.4 g) the concentration of chondroitin sulfate in plasma rises sharply over a period of 24 hours. Absolute bioavailability is 12%.

Metabolism

Chondroitin sulfate is metabolized by desulfurization (after administration of low molecular weight chondroitin sulfate).

Elimination

Chondroitin sulfate is excreted by the kidneys. The half-life is 310 min.

Indications:Osteoarthrosis of peripheral joints I-III Art.and joints of the spine.

Contraindications:

- Patients with hypersensitivity to the ingredients of this drug;

- severe renal dysfunction;

- pregnant and lactating women;

- children under 18 years of age (efficacy and safety not established).

Carefully:Diabetes mellitus, bronchial asthma, a tendency to bleeding, thrombophlebitis.

Pregnancy and lactation:

The use of the drug during pregnancy and during breastfeeding is contraindicated.

Dosing and Administration:

Assign inside before eating, without chewing, squeezed a small amount of liquid. 2 capsules 2-3 times a day. After 60 days of therapy, the dose should be gradually reduced, depending on the needs of the individual patient.

A course of treatment: 2-3 months (duration of treatment is determined by the doctor). Repeated treatment is possible only after consulting a doctor.

Side effects:

From the cardiovascular system: tachycardia.

From the central nervous system: dizziness, headache, drowsiness, insomnia.

From the digestive system: abdominal pain, flatulence, constipation, or diarrhea.

Allergic reactions: skin allergic reactions, allergic reactions, exacerbation of bronchial asthma.

Other: pain in the legs and peripheral edema.

Overdose:

Cases of drug overdose are unknown. In the event of overdose recommended gastric lavage and symptomatic therapy. Extremely high doses of glucosamine (many times higher than the recommended daily dose) can cause diarrhea or nausea, the appearance of hemorrhagic rashes.

Interaction:

It is possible to increase the effect of anticoagulants, antiplatelet agents, fibrinolytic agents. The drug increases the absorption of tetracyclines, reduces the effect of semisynthetic penicillins. The drug is compatible with glucocorticoid drugs and non-steroidal anti-inflammatory drugs.

Special instructions:

If unwanted effects from the gastrointestinal tract appear, the dose should be reduced 2-fold, and in the absence of improvement, the drug should be discontinued. If there is no clinical effect after the course of therapy for 4 weeks, the question of clarifying the diagnosis should be solved.

Effect on the ability to drive transp. cf. and fur:

During the treatment period, it is necessary to refrain from engaging in potentially dangerous activities that require increased concentration and speed psychomotor reactions.

Form release / dosage:

Capsules 250 mg + 200 mg.

Packaging:

For 5, 6 or 10 capsules in a contour mesh box made of polyvinylchloride film and aluminum foil printed lacquered.

10, 20, 30, 40, 50, 60, 100 or 120 capsules in a drug polymer container sealed with a high-pressure polyethylene lid with a first opening control or a low-pressure polyethylene lid with a first opening control or a polypropylene lid with a system "click-turn".

One jar or 1, 2, 3, 4, 5, 6, 10 or 12 contour mesh packages together with the instruction for use are placed in a cardboard package (bundle).

Storage conditions:

At a temperature of no higher than 25 ° C.

Keep out of the reach of children.

Shelf life:

3 years.

Do not use after expiry date.

Terms of leave from pharmacies:Without recipe

Registration number:LP-004329

Date of registration:06.06.2017

Expiration Date:06.06.2022

The owner of the registration certificate:TRIVIUM-XXI, LLC TRIVIUM-XXI, LLC Russia

Manufacturer: & nbsp

OZONE, LLC Russia

Information update date: & nbsp09.10.2017

Illustrated instructions

Instructions

Arthravir®-complex-INCAMFARM® (Artravir-complex-Inkamfarm)